ArticleArchives of microbiology2026
Probiotic and immune-modulatory capacities of three human gut-derived strains of Parabacteroides distasonis.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human gut microbiome harbors diverse beneficial bacteria with potential roles in supporting host health. Parabacteroides distasonis has recently attracted interest as a next-generation probiotic (NGP) candidate; however, functional evidence for human-derived strains remains limited. Here, three human gut-derived P. distasonis strains (B2-S-102, B2-Q-110, and Y3-G-102) were isolated from healthy individuals and characterized using comparative genomics and in vitro functional assays. Species-level identity was supported by 16S rRNA gene analysis and whole-genome relatedness metrics (ANI > 97% and dDDH > 70%), consistent with established species delineation thresholds. Under controlled laboratory conditions, the strains showed tolerance to acidic pH (pH 2.0), bile salts (0.3%), and simulated gastric and intestinal fluids. Functionally, the strains exhibited measurable antioxidant activity (35.03 ± 7.76% to 51.22 ± 5.60% DPPH inhibition) and α-amylase inhibitory activity (51.03 ± 32.12% to 69.23 ± 4.26%) in vitro. Cell-free supernatants inhibited albumin denaturation (47.65 ± 3.56% to 65.26 ± 4.15%), while live bacteria reduced nitric oxide production and pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ, and IL-1β) in LPS-stimulated RAW 264.7 macrophages (p < 0.05). The strains also displayed in vitro growth-inhibitory activity against Escherichia coli, Acinetobacter baumannii, and Salmonella enteritidis. Genome mining identified multiple biosynthetic gene clusters, indicating genetic potential for secondary metabolite production; however, expression and metabolite identity were not experimentally validated. No haemolytic activity was observed, supporting a favorable preliminary safety profile. Overall, these findings provide preliminary in vitro evidence supporting the potential of human-derived P. distasonis strains as NGP candidates for further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.